Neo Ivy Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Neo Ivy Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-118,357	Closed	-$2.55M	–	488
2025 Q4	$2.55M	Buy	+118,357	New	+$2.49M	0.4%	99
2023 Q4	$197K	Buy	+2,038	New	+$196K	0.44%	74
2022 Q4	$333K	Buy	+2,568	New	+$298K	0.23%	188
2022 Q2	–	Sell	-4,752	Closed	-$372K	–	602
2022 Q1	$372K	Buy	4,752 +256	+6%	+$19.6K	0.34%	114
2021 Q4	$405K	Buy	+4,496	New	+$384K	0.58%	41
2020 Q4	–	Sell	-746	Closed	-$104K	–	564
2020 Q3	$104K	Buy	+746	New	+$113K	0.11%	283
2020 Q2	–	Sell	-1,783	Closed	-$174K	–	593
2020 Q1	$174K	Buy	+1,783	New	+$204K	0.28%	139
2019 Q3	–	Sell	-4,565	Closed	-$694K	–	387
2019 Q2	$694K	Buy	+4,565	New	+$555K	0.39%	131

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neo Ivy Capital Management's SRPT Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 118,357 shares — an estimated $2.55M sold.

Neo Ivy Capital Management first reported a position in SRPT in Q2 2019 and held it in 8 quarters. The position peaked at $2.55M in Q4 2025. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Neo Ivy Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
Neo Ivy Capital Management sold 118,357 Sarepta Therapeutics shares in Q1 2026, an estimated $2.55M.
Neo Ivy Capital Management first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 8 quarters.
Neo Ivy Capital Management's Sarepta Therapeutics position peaked at $2.55M in Q4 2025.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.